首页> 美国卫生研究院文献>Frontiers in Pharmacology >Therapeutic Efficacy and Safety of Paeoniae Radix Rubra Formulae in Relieving Hyperbilirubinemia Induced by Viral Hepatitis: A Meta-Analysis
【2h】

Therapeutic Efficacy and Safety of Paeoniae Radix Rubra Formulae in Relieving Hyperbilirubinemia Induced by Viral Hepatitis: A Meta-Analysis

机译:Pa药丹参配方缓解病毒性肝炎引起的高胆红素血症的疗效和安全性的荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: Hyperbilirubinemia is one of the most devastating pathologies induced by various liver diseases. Formulae related to Paeoniae Radix Rubra (PRR) at high doses have been applied to treat hyperbilirubinemia in traditional Chinese medicine (TCM). The aim of this systematic review and meta-analysis is to assess the efficacy and safety of formulae relevant to high-dose PRR in patients suffering from hyperbilirubinemia induced by viral hepatitis.>Methods: We performed a meta-analysis of randomized-controlled clinical trials to evaluate the efficacy and safety of formulae that apply a high dose of PRR for hyperbilirubinemia. Seven databases were searched until April, 2015. All studies were included according to detailed criteria and assessed for methodological quality. The outcome measurements were recorded for further analysis using the RevMan 5.2.11 software.>Results: Fifteen articles involving 1323 patients with hyperbilirubinemia were included. Formulae with high-dose PRR might promote the efficacy of either a combined application ([OR: 3.98, 95% CI (2.91, 5.43)]; P < 0.01) or a single application ([OR: 4.00, 95% CI (1.50, 10.68)]; P < 0.01) for hyperbilirubinemia. The indices of TBIL, ALT, and AST significantly decreased ([MD: –75.57, 95% CI (−94.88, −56.26)], [MD: −26.54, 95% CI (−36.19, −16.88)], and ([MD: −28.94, 95% CI (−46.26, −11.61)]; P < 0.01), respectively. In addition, formulae with high-dose PRR could enhance the treatment efficacy of hyperbilirubinemia triggered by hepatitis B ([OR: 2.98, 95% CI (1.75, 5.05)]; P < 0.01). Furthermore, the efficacy was enhanced with an increasing dosage of PRR. Two articles reported that no side effects occurred in clinical trials, and three studies noted that patients presented light digestive tract symptoms.>Conclusion: Formulae relevant to high-dose PRR ameliorate hyperbilirubinemia and might constitute a promising therapeutic approach. For widespread acceptance by practitioners, more rigorously designed multicenter, double-blind, randomized, and large-scale controlled trials are required.
机译:>目的:高胆红素血症是各种肝病引起的最具破坏性的病理之一。与高剂量Pa药(Paeoniae Radix Rubra)(PRR)有关的配方已被用于治疗中药(TCM)中的高胆红素血症。该系统评价和荟萃分析的目的是评估与大剂量PRR相关的配方在病毒性肝炎引起的高胆红素血症患者中的有效性和安全性。>方法:我们进行了荟萃分析随机对照临床试验以评估将高剂量PRR用于高胆红素血症的配方的有效性和安全性。直到2015年4月,共检索了七个数据库。所有研究均根据详细标准纳入,并评估了方法学质量。使用RevMan 5.2.11软件记录结果测量结果以进行进一步分析。>结果:纳入15篇涉及1323例高胆红素血症患者的文章。具有高剂量PRR的配方可能会提高联合应用([OR:3.98,95%CI(2.91,5.43)]; P <0.01)或单次应用([OR:4.00,95%CI(1.50) ,10.68)]; P <0.01)治疗高胆红素血症。 TBIL,ALT和AST的指数显着降低([MD:–75.57,95%CI(−94.88,-56.26)],[MD:−26.54,95%CI(−36.19,-16.88)],和( [MD:−28.94,95%CI(−46.26,-11.61); P <0.01)另外,高剂量PRR的配方可以增强由乙型肝炎引发的高胆红素血症的治疗效果([OR:2.98 ,95%CI(1.75,5.05)]; P <0.01)。此外,随着PRR剂量的增加,疗效增强。两篇文章报道临床试验中未见副作用,三篇研究指出患者消化道消化不良>结论:与大剂量PRR相关的配方可改善高胆红素血症,可能构成一种有前途的治疗方法。需要进行对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号